Alvotech announces approval of AVT 03, a biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area
Alvotech announced that the European Commission (EC) has approved AVT 03 as a biosimilar to Prolia and Xgeva (denosumab). AV T03 is approved in two presentations: as a… read more.
